Corbus Pharmaceuticals
CRBP
Market cap $212M

17.64 USD

-0.03

0.17%

Updated Oct 22, 10:47 AM EDT

1 day

-0.17%

5 days

-6.52%

1 month

-7.11%

3 months

-69.74%

6 months

-53.21%

Year to date

178.67%

1 year

204.66%

5 years

-88.60%

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 19

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

100% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]

42% more capital invested

Capital invested by funds: $341M [Q1] → $486M (+$145M) [Q2]

30% more funds holding

Funds holding: 82 [Q1] → 107 (+25) [Q2]

17.64% more ownership

Funds ownership: 82.95% [Q1] → 100.59% (+17.64%) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

22% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $1.52M

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$40

127%

upside

Avg. target

$74

319%

upside

High target

$88

399%

upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andrew Fein 49% 1-year accuracy 62 / 126 met price target	354%upside $80	Buy Reiterated	23 Sept 2024
B. Riley Securities Kalpit Patel 75% 1-year accuracy 6 / 8 met price target	127%upside $40	Buy Maintained	20 Sept 2024
Wedbush Robert Driscoll 53% 1-year accuracy 26 / 49 met price target	189%upside $51	Outperform Maintained	20 Sept 2024
Mizuho Graig Suvannavejh 59% 1-year accuracy 17 / 29 met price target	320%upside $74	Outperform Reiterated	20 Sept 2024
RBC Capital Brian Abrahams 56% 1-year accuracy 38 / 68 met price target	365%upside $82	Outperform Reiterated	20 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CRBP published over the past 30 days

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg) and will be followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommended/optimized doses and seek preliminary efficacy signals.

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

24/7 Wall Street

Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More

24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.

Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets' Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Corbus Pharmaceuticals Holdings, Inc. CRBP received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s NVO mid-stage data on its obesity drug.

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Investors Business Daily

Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects

24/7 Wall Street

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Zacks Investment Research

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Zacks Investment Research

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why

Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why

See News Rankings

Charts implemented using Lightweight Charts™